AstraZeneca

Astrazeneca’s Experimental Drug to Treat COPD Fails to Reduce Acute Exacerbations

Astrazeneca’s Experimental Drug to Treat COPD Fails to Reduce Acute Exacerbation

On Monday, AstraZeneca PLC announced that Phase IIa study of benralizumab, an experimental drug for the treatment of Chronic Obstructive Pulmonary Disease (COPD), was published in 'The Lancet Respiratory Medicine' medical journal.

This drug is specially designed for the patients who do not respond effectively to the traditionally available inhalers. COPD is a disease related to smoking.

Location: 
Laboratories: 
Company: 

AstraZeneca, Roche and Qiagen to Collaborate for Cancer Diagnostic

AstraZeneca, Roche and Qiagen to Collaborate for Cancer Diagnostic

AstraZeneca has signed up an agreement of collaboration with Roche AG and Qiagen for cancer diagnostic technology using genomic data from plasma samples. The companies will share technology and research expertise to develop new blood test.

Qiagen's EGFR test has been approved by FDA and the new test will be using EGFR as base technology. The companies will work together to develop two diagnostic blood tests. The test will indicate the benefits lung cancer patients can derive from the drugs.

Location: 

AstraZeneca’s Early-Stage Trials of Experimental Cancer Drug are Encouraging

AstraZeneca’s Early-Stage Trials of Experimental Cancer Drug are Encouraging

At the annual American Society of Clinical Oncology (ASCO) meeting held in Chicago, Britain's AstraZeneca Plc announced about fruitful results from early-stage trials of its experimental cancer drug, MEDI4736.

Sharing the data, the company said they can move into pivotal-stage testing. MEDI4736 is part of closely monitored drugs called as anti-PDL1 therapies. They work by stopping a tumor's ability to escape immune system's defenses.

Location: 
Company: 

U.S. Food and Drug Administration Approves AstraZeneca Farxiga Tablets

U.S. Food and Drug Administration Approves AstraZeneca Farxiga Tablets

The U.S. Food and Drug Administration review team has approved Farxiga (dapaglifozin) tablets to enhance glycemic control with diet and exercise in adults suffering from type 2 diabetes.

Company: 

FDA Moots Effect of New Diabetes Drug on Bladder and Breast Cancer Patients

FDA Moots Effect of New Diabetes Drug on Bladder and Breast Cancer Patients

A diabetes pill from Bristol-Myers Squibb and AstraZeneca has put the Food and Drug Administration in a fix. The drug, Dapagliflozin, is being used to cure type 2 diabetes patients by reducing excess sugar in their urine, apparently, quite different from the previous drugs used.

News: 
Location: 

Popular Stories

Harley-Davidson to turn 8 Dyna motorbikes into new Softail bikes

Betting big on cruisers, the luxury motorcycle... Read More

Uber’s net loss declines as ride bookings grow

Uber Technologies reported lower loss by nearly 9... Read More

Samsung Galaxy Note 8 facing challenges on multiple fronts

The Samsung Galaxy Note 8 is facing an increasingly... Read More

Leaked reports reveal more about new BMW M5

Luxury carmaker BMW’s next-generation M5 car will... Read More

Tesla announces risky new approach to customer service

During the past few years, Tesla was slammed by a... Read More